Estrogen Prescribing Rose 184%. A Perimenopause Platform Shut Down Last Week

Reimbursement attaches to menopause at the pharmacy counter and in the exam room. The layer in between has no claim to file.

Truveta Research published an analysis on April 9, 2026 drawing on electronic health record data from its member health systems, measuring estrogen-based hormone therapy prescribing from 2018 through March 2026.

Among women aged 45 to 54 in that population, the share with an estrogen-based prescription rose 184.2% across the period, reaching 1 in 20 by February 2026.

The denominator is care-seeking women with records in participating systems rather than a census sample, so the series describes patients already inside the health system. The FDA's own numbers point the same way. Requesting labeling changes in November 2025, the agency cited roughly 41 million US women aged 45 to 64 in 2020 against approximately 2 million aged 46 to 65 who received a systemic prescription that year, a ratio near 5%. It does not reconcile the mismatched age bands.

On February 12, 2026, the FDA approved removal of cardiovascular disease, breast cancer, and probable dementia language from the boxed warnings of six menopausal hormone therapy products, the first batch of an action for which 29 drug companies had submitted proposed labeling changes.

It also cited a 2021 study putting moderate-to-severe vasomotor symptom prevalence at approximately 34% of women aged 45 to 65, which is the gap between who has symptoms and who gets treated, stated by the regulator itself.

Six months into the largest rise in menopause prescribing in twenty years, Play Health announced on August 12 that it is shutting down.

Menopause care gets paid for in two places, when a prescription is filled and when a patient sees a clinician. Work done in between has no billing code attached to it, which means it has no reliable buyer.

Play Health launched in 2025, giving patients a place to log symptoms, medications, cycles, and habits between appointments and generating care plans for their clinicians. Co-founder and chief executive Andrea Mazzocchi announced the closure on LinkedIn, writing that the company could not find a place in healthcare, whether cash pay or insurance covered, where the product fit.

She added that while similar technologies help manage chronic diseases carrying high mortality and hospitalization rates, improved menopause care is still treated as a nice to have. The platform goes inactive on September 9, leaving a window for users and clinicians to export their data.

One closure does not settle a category, and the company's funding history is not public in a form that can be verified. What the account supplies is a specific claim about reimbursement structure, and that claim is checkable.

The same thing happened in maternal health two years ago. Ruth Health wound down in November 2024 after building remote services around doula support, pelvic floor training, and cesarean recovery. Co-founder and chief executive Alison Greenberg wrote on LinkedIn that the decision followed reflection on a fragmented maternity care space where the company failed to find scalable product-market fit.

Different life stage, different clinical problem, and no claim to file in either case.

Take the prescription first. Filling one generates a pharmacy claim against a national drug code, and the volume shows up in manufacturer results.

Amneal reported second quarter 2026 net revenue of $796 million on July 30, up 10% from $725 million a year earlier. Its Affordable Medicines segment, which carries the company's women's health portfolio, took in $489.9 million against $433.4 million in the same quarter of 2025, a rise of 13%.

On the earnings call, co-chief executive Chirag Patel said demand for the estrogen patches the company manufactures in New Jersey has lines running 24 hours a day, and that equipment is secured to triple capacity by next year. Full year capital expenditure guidance was raised to approximately $150 million from approximately $110 million.

Now the visit. An evaluation and management appointment generates a medical claim, and that is the model behind the category's largest recent raise.

Midi Health closed $100 million in a Series D on February 3, 2026 at a valuation above $1 billion, and states that its insurance-covered services reach more than 45 million women across all 50 states, seeing more than 25,000 patients each week. Those figures are company-stated and not independently verified.

A patch generates a claim. A visit generates a claim. Symptom tracking between the two generates nothing, because no code covers it.

Remote physiologic monitoring, billed under CPT 99453, 99454, 99457, and 99458, requires physiologic parameters collected by a medical device and transmitted to a clinician. Weight, blood pressure, pulse oximetry, and respiratory flow rate are the examples written into the code descriptors.

A patient reporting how bad her hot flashes were last night is not a physiologic parameter, and a phone is not a medical device.

Remote therapeutic monitoring was built for non-physiologic data, which is closer, but its device-supply codes are scoped by body system. CPT 98976 covers respiratory. CPT 98977 covers musculoskeletal. CPT 98978 covers cognitive behavioral therapy. The CY2026 physician fee schedule added shorter-duration variants and no endocrine or hormonal category.

Diagnosis coding says the same thing from the other side. Menopause is billable under ICD-10 code N95.1, menopausal and female climacteric states, sitting in Chapter 14 among diseases of the genitourinary system. N95.1 is not classified as a complication or comorbidity in the MS-DRG grouper, meaning it adds no severity weight to a hospital stay.

A perimenopausal patient can qualify for chronic care management on the strength of hypertension or diabetes or depression. She does not qualify on the strength of menopause.

Doctors can bill for diagnosing menopause. Nobody can bill for managing it between appointments.

That leaves a company doing this work with three options, none of them a claim. It can charge patients directly and compete on retention against a symptom set that eventually resolves on its own. It can sell to employers. Or it can sign a contract that pays it out of the medical costs it prevents, which requires proving savings the published evidence cannot yet prove.

The employer option is thinner than its reputation. Maven Clinic's 2026 benefits report, surveying 2,071 human resources and benefits professionals across four countries in November 2025, found 21% of those organizations include menopause-specific benefits against 40% offering fertility services. It is a vendor-run survey of that vendor's own customers.

The economic case those buyers act on traces to Faubion and colleagues in Mayo Clinic Proceedings, 2023, which estimated $1.8 billion in annual US lost work time, rising to $26.6 billion with medical expenses included. The estimate rests on 4,440 employed respondents at four Mayo Clinic sites, a 16.1% response rate, of whom 93% were White and 59.3% held a college degree or above. The authors called for further study in larger and more diverse groups. Benefits committees now cite the dollar figure without the four sites, the response rate, or the caveat.

The company worth studying is not another menopause business. It is FamilyWell Health, founded by neonatologist Jessica Gaulton after her own postpartum depression, which puts perinatal mental health clinicians inside obstetric practices.

The company states its founding insight plainly, integrating mental health support into obstetric care using collaborative care billing codes. Those codes already existed. CPT 99492, 99493, and 99494 cover psychiatric collaborative care management, and 99484 covers general behavioral health integration, reimbursable across commercial, Medicare, and Medicaid plans without individual contract negotiation.

FamilyWell did not persuade payers that maternal mental health deserved coverage. It found the code that already paid for the model and built the service to fit inside it.

That is the move worth copying. Build to a code that exists rather than waiting for one to be written, because the second path takes years and depends on the American Medical Association and CMS rather than on the company.

For anyone running a women's health product today, the first roadmap question is not whether the intervention improves outcomes. It is which existing code the work bills under, and what the service has to look like to satisfy that code's documentation requirements.

Care between visits that generates no claim has to be paid for by something else in the business, which usually means it ends up as a free feature attached to a prescribing or visit product rather than a product anyone sells.

A monitoring code covering hormonal symptom data would turn a large amount of currently unpaid work into claims. Nothing in the CY2026 rule indicates one is coming.

That leaves hardware, and explains why a ring company's patent filings matter more here than its product launches.

The US Patent and Trademark Office granted Oura Health Oy patent 12551116 on February 17, 2026, filed in November 2023, covering methods for determining blood pressure from the timing of a pulse travelling between two points on the body. In the same six weeks it granted patent 12551197 for predicting menstrual cycle onset from temperature data and patent 12558022 for identifying menstrual cycle phases. Blood pressure is one of the four measurements named in the remote monitoring code descriptors.

Wareable reported on August 12 that a further filing extends the blood pressure work to flagging preeclampsia and gestational hypertension in pregnancy. Oura did not comment, and I have not located that application number, so treat it as reported rather than confirmed.

The three granted patents make the point without it. A ring produces the physiologic readings the codes ask for, and a symptom log does not, so the companies best placed to bill for women's health monitoring are the ones already selling a device.

For twenty years what menopause care lacked was attention. What it lacks now is a billing code.

The Luteal covers the business, science, and policy of women's health. Nothing here is medical advice.